Christopher Keir

Christopher Keir, MD, MS, currently serves as Vice President at ADC Therapeutics since November 2023, following a tenure as Senior Vice President of Medical Science Advocacy at EQRx and Vice President of Medical Affairs at GRAIL, Inc. Experience also includes leading Global Medical Affairs at Array BioPharma Inc. and holding the position of Global Head of Medical Affairs for Cell and Gene Therapy at Novartis. Christopher's earlier roles include Fellowship in Hematology and Oncology at Weill Cornell Medicine and Instructor at Harvard Medical School. Educational credentials feature a Doctor of Medicine from Georgetown University School of Medicine, a Master’s Degree in Biophysics and Physiology from Georgetown University, and a Bachelor’s Degree in Biology and Art History from Duke University, complemented by a brief scholarship at the University of Oxford in English Literature.